$AUPH - On our trading list. Congrats if you got in in the $5S and tripled your money already! Aurinia Pharmaceuticals price target raised to $32 from $25 at H.C. WainwrightH.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $32 from $25 citing the company's "robustly positive" data from the Phase 3 AURORA study of voclosporin. The analyst believes voclosporin is almost assuredly to become the first treatment ever approved for lupus nephritis. He reiterates a Buy rating on Aurinia Pharmaceuticals. $AUPH, Aurinia Pharmaceuticals Inc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page